SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 11, 2026

DNTH

Dianthus Therapeutics, Inc. /DE/
BEARISH
Impact 6/10
Horizonweeks Processed3mo ago
Insider cluster: 2 insiders, $1.2M total
Actionable Insight ▼ Bearish

The CEO's ~$18.9M sale is the dominant signal, it is large, concentrated, and not offset by any insider buying. While the sales follow option exercises (tax-driven), the sheer size and timing suggest potential caution. Monitor for any upcoming clinical data readouts, earnings, or financing events that could explain the selling. The 95% bullish analyst consensus creates a potential asymmetry if negative news emerges.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$112.41
T+0 close · Aug 11, 2026 · via day close
Latest settled
−26.15%
T+60 · $83.01
Vs SPY
−21.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $112.41entry
  2. T+1 · 3mo ago −2.50%α −3.20% · $109.60
  3. T+5 · 3mo ago +1.15%α +1.59% · $113.70
  4. T+20 · 2mo ago −8.12%α −6.22% · $103.28
  5. T+60 · 12d ago −26.15%α −21.04% · $83.01

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Marino Garcia and General Counsel Adam Veness executed a cluster of open-market sales totaling ~$20.0M over two days (Aug 7-10, 2026), following option exercises at much lower strike prices. The CEO alone sold ~$18.9M at ~$108-111/share, while the GC sold ~$2.2M. These are large, concentrated sales by top executives at a $6.3B biotech with a 95% bullish analyst consensus, creating a notable bearish signal that warrants close monitoring.

Key Financial Metrics

Direction
selling
Total Value
$20.0M
Insiders
2

Key Facts

  • CEO Marino Garcia sold 166,000 shares in open-market transactions on Aug 7, 2026, totaling ~$18.9M at prices between $107.49 and $110.76.
  • General Counsel Veness sold 20,000 shares on Aug 7 and 10, 2026, totaling ~$2.2M at prices between $110.38 and $111.18.
  • All sales followed option exercises: CEO exercised 292,000 options at $0-$8.44 strike; GC exercised 23,833 options at $0-$17.88 strike.
  • Total open-market sales by the two insiders in the cluster: ~$20.0M, representing approximately 0.32% of DNTH's $6.3B market cap.
  • The cluster occurred within a 7-day window (Aug 7-10), with no open-market purchases by any insider.
  • DNTH has a 95% bullish analyst consensus (21 Buy, 1 Hold) and $6.3B market cap.

Financial Impact

Insider sales of ~$20.0M represent 0.32% of market cap, modest in proportionality but significant in absolute dollar terms and executive seniority.

insider ownershipmarket sentiment

Risk Factors

  • CEO selling ~$18.9M in a concentrated window could signal management's view that the stock is fully valued or that near-term catalysts are uncertain.
  • No insider buying to offset the selling, the cluster is entirely one-directional (sell).
  • Biotech stocks are binary event-driven, large insider sales ahead of data readouts can be a red flag.
  • The stock has rallied significantly (options exercised at $8.44 vs. sale price ~$108), creating a natural profit-taking incentive.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-DNTH-1786482561581

Track record

23 reports on DNTH

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026